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Development and evaluation of ritonavir hollow microballoons for floating drug delivery 
 
Abstract 
Ritonavir is human immunodeficiency virus (HIV) proteaseinhibitor used as the antiretroviral 
agent. The objective of the present investigation was to formulate and evaluate Ritonavir gastro-
retentive floating microballoons for controlled release. Different batches of microballoons were 
prepared by the emulsion solvent diffusion method. The resultant microballoons were evaluated 
for percentage yield, entrapment efficiency, particle size, and in vitro drug release, stability 
study. The densities of floating microspheres were found to be less than the density of gastric 
fluid (1.004 g/cm
3
). The entrapment efficiency of preparedfloating microspheres was satisfactory 
(68.37 to 88.52%). Among all formulations, FM1 prepared with polymer HPMC was found to be 
the best as it exhibited highest drug release (89.07%) in 12 hrs and was stable for three months at 
ambient conditions. 
Key words: Hollow microballoons, floating drug delivery,Ritonavir, in vitro drug release, 
gastro-retentive. 
INTRODUCTION 
 The oral route is being used for the delivery of therapeutic agents because of different 
advantages including the low cost of the therapy and ease of administration lead to high levels of 
patient compliance. More than 50% of the drug deliverysystems available in the market are oral 
drug delivery systems
1
. The purpose of any drug delivery system is to provide a therapeutic 
amount of drug to the proper site in the body to attain promptly andthen maintain desired drug 
concentration
2
.  
Drugs that are easily absorbed from the gastrointestinal tract and have a short half-life are 
eliminated quickly from the blood circulation, so there is a need of frequent dosing to maintain 
therapeutic concentration of drug. To eliminate this limitation, the oral sustained controlled 
release formulations have been developed in an attempt to release the drug slowly into the 
gastro-intestinal tract and maintain an effective drug concentrationin the blood over long period 
of time
3
. Floating systems or dynamically controlled systems are low-density systems that have 
sufficient buoyancy to float over the gastric contents and remain buoyant in the stomach without 
affecting the gastric emptying rate for a prolonged period of time. While the system floats over 
the gastric contents, the drug is released slowly at the desired rate. Conventional oral dosage 
forms do not offer any control over drug delivery and cause greatfluctuations in plasma drug 
concentrations
4
. 
Ritonavir is human immunodeficiency virus (HIV) protease inhibitor primarily absorbed from 
stomach used as the antiretroviral agent
5,6
. 
MATERIALS AND METHODS 
Materials 
Ritonavir was obtained from Silva Hill Pharma Limited, Nigeria city, Eudragit L 100  and 
hydroxypropyl methylcellulose (HPMC) were purchased from the Jagal Pharmaceutical, Lagos, 
Nigeria. All other chemicals used were of analyticalreagent grade. 
Preparation of floating microballoons 
Floating microballoons were prepared by the emulsion solvent diffusion method. Ritonavir, 
Eudragit L100 and HPMC were dissolved in a mixture indifferent ratio in ethanol and 
dichloromethane (table 1). The resulting solution was added slowly to stirred 250 mL of aqueous 
solution of 0.50% (w/v) PVA at room temperature. The stirring was done for 2 hrs at 1000-1200 
 rpm by mechanical stirrer equipped with four bladed propellers, to evaporate the volatile solvent. 
The floating microballoons formed were screened (#12), washed with water and dried at 
roomtemperature in a desiccator for 24 hrs
7
. 
 
Table-1: Composition of floating microballoons formulations of Ritonavir 
 
 
 
 
 
 
 
 
 
 
EVALUATION OF MICROBALLOONS 
a. The percentage yield  
It was determined by weighing the Ritonavir hollow microballoons after drying. The percentage 
yield was calculated as follows
8
: 
% Yield =(Total weight of hollow microballoons )/( Total weight of drug and polymer) X 100 
b. Micromeritic properties 
1. Tapped density
9 
Tapped density of Ritonavir hollow microballoons was determined by the tapping method. 
Accurately weighed quantity of hollow microballoons wastransferred in to a 10 ml measuring 
cylinder. After observing the initial volume of floating microballoons, the tapping was continued 
on a hard surface until no further change in volume was noted and the tapped density was 
calculated according to following formula: 
Tapped density =(Mass of hollow microballoons )/(Volume of  hollow microballoons after 
tapping ) X 100 
2. Angle of repose
10 
The angle of repose of Ritonavir hollow microballoons was determined by fixed funnel method. 
The hollow microballoons were allowed to fall freelythrough a funnel until apex of conical pile 
just touched the tip of the funnel. 
 Angle of repose is determined by following formula:  
tan θ= h/r 
Where,  
θ = angle of repose,  h = height of the cone, r = radius of the cone base   
3. Carr’s Index11  
It indicates the ease with which a material can be induced to flow and powder compressibility. It 
is expressed in percentage and is given by  
Carr,s Index= (Tapped density-Bulk density)/(Tapped density) x100 
4. Hausners ratio
12
  
Hausner ratio (Hr) is an indirect index of ease of powder flow. It is calculated by the following 
formula:  
Hausner^' s ratio= (Tapped density)/(Bulk density) 
Batch 
code 
Eudragit 
L100 
(mg) 
HPMC 
(mg) 
Di-chloromethane 
:Ethanol 
::1:1 
FM1 - 300 10 
FM2 300 - 10 
FM3 150 150 10 
FM4 100 200 10 
FM5 200 100 10 
 c. Buoyancy study
13 
Ritonavir microballoons (100 mg) were placed in 0.1 N HCI (300 ml) containing 0.02% Tween 
20 and stirred at 100 rpm. The layer of buoyantmicroballoons was pipetted and separated by 
filtration at 1, 2, 4 and 6 h. The collected microballoons were dried in a desiccator over night. 
The percentage of microballoons was calculated by the following equation: 
 
% Buoyancy =(Weight of floating microballoons at time t)/(Initial weight of microballoons ) X 
100 
d. Drug entrapment efficiency
14 
Ten mg of hollow Ritonavir microballoons from all batches were accurately weighed and 
crushed. The powdered microballoons were dissolved with 10 ml ethanol in 100 ml volumetric 
flask and volume was made up with 0.1 N HCl. The resultingsolution is then filtered (Whatmann 
filter paper No. 44), suitably diluted and the absorbance was measured at 246 nm against 0.1 N 
HCI as blank. The percentage drug entrapment was calculated as follows: 
% DEE =(Calculated drug concentration )/( Theoretical drug concentration) X100 
e. In vitro release studies
15 
A 12 hrs study of drug release rates from floating Ritonavir microballoons was carried out using 
USP type II dissolution paddle assembly. Floating microballoons equivalent to 100 mg drug 
were dispersed in 900 ml of 0.1 N HCI pH 1.2 maintained at 37±0.5°C and stirred at 100 rpm. 
Five ml sample was withdrawn at predetermined intervals while replacing equal amount of fresh 
dissolution medium. The samples were filtered,suitably diluted and analyzed 
spectrophotometrically at 246 nm to determine the concentration of drug present in the 
dissolution medium. 
Drug release kinetic data analysis 
The dissolution data of all the formulations was fitted to zero order, Higuchi matrix and 
Korsemeyer-Peppas to ascertain the kinetic modeling of drug release.The value of ‘n’ gives an 
indication of the release mechanism. When n = 1, the release rate is independent of time (typical 
zero order release / case II transport); n = 0.5 for Fickian release (diffusion/ case I transport); and 
when 0.5<n<1, anomalous (non-Fickian or coupled diffusion/ relaxation) are implicated. Lastly, 
when n>1.0 super case II transport is apparent
16
. 
f. Stability study 
From the prepared Ritonavir microballoons, best formulationwas selected on basis of buoyancy 
and the percentage drug released. The selected formulation was placed in borosilicate screw 
capped glass containers and stored at different temperatures (27±2°C), oven temperature 
(40±2°C) and in the refrigerator (5-8°C) for a period of 3 months. The samples were assayed for 
drug content at regular intervals
17
. 
RESULTS AND DISCUSSION 
The hollow microballoons of Ritonavir were successfully prepared using Eudragit L100 and 
HPMC as a polymer by emulsion solvent diffusion method. 
Mean particle size range was varied from 543 to 928 mm and was found to be affected by change 
in drug and polymer ratio. In general if sizes of microballoons areless than 500 mm, release rate 
of drug will be high and floating ability will reduce, while if size lies in the range of 500-1000 
mm, the floating ability will be more and release rate will be in sustained manner. So the 
prepared microballoons are having particle size range suitable for floating
18
. 
Density values for all formulations were less than that of gastric fluid (1.004 g/cm
3
), suggesting 
that they exhibit good buoyancy. The floating ability pattern differed according to the 
 formulation tested and medium used. Microballoons formulation of batch FM1 showed the best, 
85.23% floating ability in 0.1 N HCl. This can be mainly due to its low bulk density value 
obtained before and after tapping respectively. Themicroballoons remain buoyant for prolonged 
time over the surface of the dissolution medium without any apparent gelation, which might be 
responsible for good floating property. 
All formulations showed excellent flowability as represented in the terms of angle of repose 
(<40°). All the formulations showed satisfactory entrapment efficiency ranging in 68.37 to 
88.52%. 
Percentage drug release for the formulations FM1, FM2, FM3 and FM4 was found to be 89.07%, 
66.14%, 58.43% and 77.43% respectively in 12 hrs. It was observed that drug release rate 
increased by increasing the ratio of HPMC respectively. 
FM1 formulation showed appropriate balance betweenbuoyancy and drug release rate of which 
is considered as a best formulation. 
Table 2: Micromeritic properties of Ritonavir microballoons formulations. 
Code Mean particle 
size 
(mm)  
Bulk density 
(gm/cm
3
) 
Tapped density 
(gm/cm
3
) 
Hausners 
ratio 
Carr’s Index Angle of 
repose 
FM1 928±0.56 0.741±0.24 0.801±0.42 1.08 7.49 19.32
 o
 ±0.13 
FM2 734±0.31 0.763±0.09 0.825±0.08 1.08 7.51 20.12
 o
 ±0.24 
FM3 627±0.25 0.863±0.36 0.920±0.13 1.06 6.19 15.21
 o
 ±0.09 
FM4 543±0.38 0.792±0.47 0.840±0.51 1.06 5.71 18.35
 o
 ±0.08 
 
Table-3: Different evaluation parameters of Ritonavir microballoons formulations. 
 
 
 
 
 
 
 
                                                                                                              
(Mean± S.D., n=3) 
 
Code Particle Size 
(µm) 
% Yield  Entrapment 
Efficiency (%) 
% Buoyancy 
FM1 255.03±0.57 87.34±0.36 88.52±0.08 85.23±0.08 
FM2 268.56±0.48 82.32±0.48 74.64±0.22 68.46±0.36 
FM3 270.52±0.52 75.46±0.08 68.37±0.43 80.84±0.46 
FM4 300.37±0.35 79.22±0.33 71.37±0.63 78.53±0.33 
  
 
Figure 1: In-vitro release profile of different Ritonavirmicroballoons formulations 
 KTable 4- Kinetic models applied on Ritonavir microballoons formulations. 
Code Zero order Higuchi Korsemeyer-
peppas 
FM1 0.9214 0.9763 0.9867 
n=0.4073 
FM2 0.8860 0.9565 0.9835 
n= 0.5138 
FM3 0.8761 0.9825 0.9836 
n=0.5836 
FM4 0.9213 0.9235 0.9937 
n=0.5367 
 
 
Figure 2: Stability study of Ritonavir microballoons formulations of batch FM1. 
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 The in vitro release data was applied to various kinetic models to predict the drug release kinetic 
mechanism.  Kinetics and mechanism of drug release from allformulation was evaluated on the 
basis of zero order, Higuchi equation and Peppas model. 
Zero order plots for all formulations were found to be linear. Higuchi plot was found to be linear, 
which indicates diffusion may be the mechanism of drug release for each formulation. 
Correlation coefficient (r
2
) and slope value for each equation in the range of (0.9835-0.9937 and 
n in the range of 0.4073- n=0.5836 for Peppas model. Peppas plot was found with good linearity, 
its n>0.5 for all formulations, indicating that drug release may follow anomalous diffusion. 
Stability study was carried out for the FM1 formulation by exposing it to 5-8°C, 27°C. There 
was no remarkable change in content of FM1 formulation during 3 months/ 12 weeks. 
CONCLUSION 
Floating hollow microballoons of Ritonavir were successfully prepared using Eudragit L100 and 
hydrophilic polymer HPMC by emulsion solvent diffusion method. 
Floating hollow microballoons of different size and drug content could be obtained by varying 
the formulation variables. Prepared hollow microballoons of Ritonavir showed excellent 
micromeritic properties, good buoyancy and prolonged drug release for 12 hrs.  
Thus the prepared floating microballoons may prove to bepotential candidates for multiple-unit 
delivery devices adaptable to any intra gastric condition. 
Based on different parameters i.e. micromeritic properties, entrapment efficiency, drug content, 
in-vitro release study and stability study floating hollow microballoons of batch FM1 were found 
to an optimum formulation. 
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